Welcome!

Critical Biologics Corporation (CBC), based in Cambridge, MA, is a small biotechnology company committed to making available innovative products to address the many unmet medical needs in Critical Care Medicine. We believe that the traditional commercial approach of targeting a single facet of a therapydrug, device, diagnostic, or monitor ignores the fact that often these modalities are employed together by Intensivists to treat the increasing complex diseases of their patients.

CBC’s first product in development is a theranostic therapy for the initial indication of the prevention of sepsis. This product combines SolinDx™, a diagnostic assay for plasma gelsolin, and Solinex™, a human recombinant plasma gelsolin drug to allow targeted treatment of those patients at risk of developing sepsis with the biochemical condition, low plasma gelsolin, that will potentially benefit from gelsolin administration. Gelsolin was first discovered by Dr. Tom Stossel who is the American Cancer Society Professor of Medicine at Harvard Medical School, is the Director of the Translational Medicine Division and is a Senior Physician in the Hematology Division at Brigham & Women’s Hospital. In October 2006, CBC entered into an agreement with Brigham & Women’s Hospital to license technology and intellectual property pertaining to the therapeutic and diagnostic use of plasma gelsolin to predict and preemptively treat a variety of medically and economically important conditions.